ANRis Inc.

Taking on the challenge of realizing new siRNA drug discovery that provides “less burdensome treatment” to patients with cancer, genetic diseases, etc.

Research, development, manufacturing, and sales of pharmaceuticals for nucleic acid medicine, as well as related quasi-drugs, cosmetics, reagents, and other chemical products.

Established: September 27, 2023

Address: 1-22-3 Nishiwaseda, Shinjuku-ku, Tokyo

Management team: Representative Director and CEO Daisuke Niwa

Director Kazuya Kawahara

Co-founders: Kumiko Hodo, Kazuya Kawahara, Takanori Yokota, Takeshi Wada, Hiroaki Taniguchi, Yui Kishiyama

URL: https://anris.jp

E-mail: info@anris.jp